IN8bio, Inc. (INAB)

NASDAQ: INAB · Real-Time Price · USD

0.305

+0.018 (6.39%)

Nov 4, 2024, 4:00 PM EST - Market closed

IN8bio Employees

IN8bio had 31 employees as of December 31, 2023. The number of employees increased by 5 or 19.23% compared to the previous year.

Employees

31

Change (1Y)

5

Growth (1Y)

19.23%

Revenue / Employee

n/a

Profits / Employee

-$1,030,903

Market Cap

14.26M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	31	5	19.23%
Dec 31, 2022	26	7	36.84%
Dec 31, 2021	19	5	35.71%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
Cosmos Health	123
Psychemedics	116
BiomX	71
Evaxion Biotech	49
Apollomics	45
Sol-Gel Technologies	36
Imunon	33
COSCIENS Biopharma	12

Employee Rankings

INAB News

2 months ago - IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia - GlobeNewsWire
2 months ago - IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
3 months ago - IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 - GlobeNewsWire
4 months ago - IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
5 months ago - IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 - GlobeNewsWire
5 months ago - IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire
5 months ago - IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - GlobeNewsWire
5 months ago - IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting - GlobeNewsWire